Opthea Limited
Opthea Limited
Your view on CKDXF
Overview
What the company does, where it operates, and who runs it.
About Opthea Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeremy Max Levin Ba Zoology Dphil Mb Bchir
- Headquarters
- 650 Chapel Street, South Yarra, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeremy Max Levin Ba Zoology Dphil Mb Bchir
- Headquarters
- 650 Chapel Street, South Yarra, VIC, AU
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.
The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases.
The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Opthea Limited, and the rating behind it. CKDXF last traded at $0.44; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Opthea Limited. Starting points for Opthea Limited: EPS -$0.22, beta 1.75 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Opthea Limited. Opthea Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Opthea Limited. Trailing twelve-month EPS for Opthea Limited stands at -$0.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Opthea Limited. Opthea Limited has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Opthea Limited valued side by side against its closest peers. Opthea Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Opthea Limited, and how their positions are changing. At a $601.9M market value, institutional positions materially move Opthea Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Opthea Limited executives and directors. Shares of Opthea Limited have traded between $0.29 and $0.44 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Opthea Limited. Opthea Limited is a $601.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Opthea Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Opthea Limited. Coverage tracks Opthea Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.